Skip to main content
Top
Published in: BMC Infectious Diseases 1/2015

Open Access 01-12-2015 | Research article

Effect of cotrimoxazole prophylaxis on the incidence of malaria in HIV-infected children in 2012, in Abidjan, Côte d’Ivoire: a prospective cohort study

Authors: Aïda Mounkaila Harouna, Madeleine Amorissani-Folquet, François Tanoh Eboua, Sophie Desmonde, Sylvie N’Gbeche, Edmond Addi Aka, Kouakou Kouadio, Brou Kouacou, Karen Malateste, Clarisse Bosse-Amani, Patrick Ahuatchi Coffie, Valeriane Leroy, for the IeDEA paediatric West African Study Group

Published in: BMC Infectious Diseases | Issue 1/2015

Login to get access

Abstract

Background

Cotrimoxazole prophylaxis has an antimalarial effect which could have an additional protective effect against malaria in HIV-infected children on antiretroviral therapy (ART). We measured the incidence and associated factors of malaria in HIV-infected children on ART and/or cotrimoxazole in Abidjan, Côte d’Ivoire.

Methods

All HIV-infected children <16 years, followed-up in the IeDEA West-African paediatric cohort (pWADA) in Abidjan, were prospectively included from May to August 2012, the rainy season. Children presenting signs suggesting malaria had a thick blood smear and were classified as confirmed or probable malaria. We calculated incidence density rates (IR) per 100 child-years (CY). Risk factors were assessed using a Poisson regression model.

Results

Overall, 1117 children were included, of whom 89 % were ART-treated and 67 % received cotrimoxazole. Overall, there were 51 malaria events occurring in 48 children: 28 confirmed and 23 probable; 94 % were uncomplicated malaria. The overall IR of malaria (confirmed and probable) was 18.3/100 CY (95 % CI: 13.3-23.4), varying from 4.2/100 CY (95 % CI: 1.1-7.3) in children on ART and cotrimoxazole to 57.3/100 CY (95 % CI: 7.1-107.6) for those receiving no treatment at all. In univariate analysis, age <5 years was significantly associated with a 2-fold IR of malaria compared to age >10 years (incidence rate ratio [IRR] = 2.18, 95 % CI: 1.04-4.58). Adjusted for severe immunodeficiency, cotrimoxazole reduced significantly the IR of first malarial episode (adjusted IRR [aIRR] = 0.13, 95 % CI: 0.02-0.69 and aIRR = 0.05, 95 % CI:0.02-0.18 in those off and on ART respectively). Severe immunodeficiency increased significantly the malaria IR (aIRR = 4.03, 95 % CI: 1.55-10.47).
When considering the IR of confirmed malaria only, this varied from 2.4/100 CY (95 % CI: 0.0-4.8) in children on ART and cotrimoxazole to 34.4/100 CY (95 % CI: 0.0-73.3) for those receiving no treatment at all. In adjusted analyses, the IR of malaria in children on both cotrimoxazole and ART was significantly reduced (aIRR = 0.05, 95 % CI: 0.01-0.24) compared to those receiving no treatment at all.

Conclusions

Cotrimoxazole prophylaxis was strongly protective against the incidence of malaria when associated with ART in HIV-infected children. Thus, these drugs should be provided as widely and durably as possible in all HIV-infected children <5 years of age.
Literature
1.
go back to reference World Health Organization (WHO). World malaria report 2011. Geneva: WHO; 2011. World Health Organization (WHO). World malaria report 2011. Geneva: WHO; 2011.
2.
go back to reference World Health Organization (WHO), Joint United Nations programme on HIV/AIDS (UNAIDS), United Nations Children’s Fund (UNICEF). Global HIV/AIDS response. Epidemic update and health sector progress towards Universal Access. Geneva: UNAIDS; 2011. World Health Organization (WHO), Joint United Nations programme on HIV/AIDS (UNAIDS), United Nations Children’s Fund (UNICEF). Global HIV/AIDS response. Epidemic update and health sector progress towards Universal Access. Geneva: UNAIDS; 2011.
3.
go back to reference World Health Organization (WHO). Malaria and HIV interactions and their implications for public health policy. Report of a Technical Consultation. Geneva: WHO; 2004. World Health Organization (WHO). Malaria and HIV interactions and their implications for public health policy. Report of a Technical Consultation. Geneva: WHO; 2004.
6.
go back to reference Anglaret X, Chêne G, Attia A, Toure S, Lafont S, Combe P, et al. Early chemoprophylaxis with trimethoprim-sulphamethoxazole for HIV-1-infected adults in Abidjan, Côte d’Ivoire: a randomised trial: Cotrimo-CI Study Group. Lancet. 1999;353(9163):1463–8.CrossRefPubMed Anglaret X, Chêne G, Attia A, Toure S, Lafont S, Combe P, et al. Early chemoprophylaxis with trimethoprim-sulphamethoxazole for HIV-1-infected adults in Abidjan, Côte d’Ivoire: a randomised trial: Cotrimo-CI Study Group. Lancet. 1999;353(9163):1463–8.CrossRefPubMed
7.
go back to reference Walker AS, Mulenga V, Ford D, Kabamba D, Sinyinza F, Kankasa C, et al. The impact of daily cotrimoxazole prophylaxis and antiretroviral therapy on mortality and hospital admissions in HIV-infected Zambian children. Clin Infect Dis. 2007;44(10):1361–7.CrossRefPubMed Walker AS, Mulenga V, Ford D, Kabamba D, Sinyinza F, Kankasa C, et al. The impact of daily cotrimoxazole prophylaxis and antiretroviral therapy on mortality and hospital admissions in HIV-infected Zambian children. Clin Infect Dis. 2007;44(10):1361–7.CrossRefPubMed
8.
go back to reference Kyeyune FX, Calis JCJ, Phiri KS, Faragher B, Kachala D, Brabin BJ, et al. The interaction between malaria and human immunodeficiency virus infection in severely anaemic Malawian children: a prospective longitudinal study. Trop Med Int Health. 2014;19(6):698–705.CrossRefPubMed Kyeyune FX, Calis JCJ, Phiri KS, Faragher B, Kachala D, Brabin BJ, et al. The interaction between malaria and human immunodeficiency virus infection in severely anaemic Malawian children: a prospective longitudinal study. Trop Med Int Health. 2014;19(6):698–705.CrossRefPubMed
9.
go back to reference Laufer MK, Van Oosterhout JJG, Thesing PC, Thumba F, Zijlstra EE, Graham SM, et al. Impact of HIV-associated immunosuppression on malaria infection and disease in Malawi. J Infect Dis. 2006;193(6):872–8.CrossRefPubMed Laufer MK, Van Oosterhout JJG, Thesing PC, Thumba F, Zijlstra EE, Graham SM, et al. Impact of HIV-associated immunosuppression on malaria infection and disease in Malawi. J Infect Dis. 2006;193(6):872–8.CrossRefPubMed
10.
go back to reference Bronzan RN, Taylor TE, Mwenechanya J, Tembo M, Kayira K, Bwanaisa L, et al. Bacteremia in Malawian children with severe malaria: prevalence, etiology, HIV coinfection, and outcome. J Infect Dis. 2007;195(6):895–904.CrossRefPubMed Bronzan RN, Taylor TE, Mwenechanya J, Tembo M, Kayira K, Bwanaisa L, et al. Bacteremia in Malawian children with severe malaria: prevalence, etiology, HIV coinfection, and outcome. J Infect Dis. 2007;195(6):895–904.CrossRefPubMed
11.
go back to reference Chintu C, Bhat GJ, Walker AS, Mulenga V, Sinyinza F, Lishimpi K, et al. Co-trimoxazole as prophylaxis against opportunistic infections in HIV-infected Zambian children (CHAP): a double-blind randomised placebo-controlled trial. Lancet. 2004;364(9448):1865–71.CrossRefPubMed Chintu C, Bhat GJ, Walker AS, Mulenga V, Sinyinza F, Lishimpi K, et al. Co-trimoxazole as prophylaxis against opportunistic infections in HIV-infected Zambian children (CHAP): a double-blind randomised placebo-controlled trial. Lancet. 2004;364(9448):1865–71.CrossRefPubMed
12.
go back to reference Ministère de la Santé et de la Lutte contre le SIDA. Annuaire des statistiques. Abidjan: Ministère de la Santé et de la Lutte contre le SIDA; 2012. Ministère de la Santé et de la Lutte contre le SIDA. Annuaire des statistiques. Abidjan: Ministère de la Santé et de la Lutte contre le SIDA; 2012.
14.
go back to reference Ekouevi DK, Azondekon A, Dicko F, Malateste K, Touré P, Eboua FT, et al. 12-month mortality and loss-to-program in antiretroviral-treated children: The IeDEA pediatric West African Database to evaluate AIDS (pWADA), 2000–2008. BMC Public Health. 2011;11:519.CrossRefPubMedPubMedCentral Ekouevi DK, Azondekon A, Dicko F, Malateste K, Touré P, Eboua FT, et al. 12-month mortality and loss-to-program in antiretroviral-treated children: The IeDEA pediatric West African Database to evaluate AIDS (pWADA), 2000–2008. BMC Public Health. 2011;11:519.CrossRefPubMedPubMedCentral
15.
go back to reference Organisation mondiale de la Santé (OMS). Directives pour le traitement du paludisme. 2eth ed. Genève: OMS; 2011. Organisation mondiale de la Santé (OMS). Directives pour le traitement du paludisme. 2eth ed. Genève: OMS; 2011.
16.
go back to reference World Health Organization. Severe falciparum malaria. Trans R Soc Trop Med Hyg. 2000;94, Supplement 1(0):1–90.CrossRef World Health Organization. Severe falciparum malaria. Trans R Soc Trop Med Hyg. 2000;94, Supplement 1(0):1–90.CrossRef
17.
go back to reference Organisation mondiale de la Santé (OMS), Département des Maladies transmissibles- Surveillance et Action. Normes recommandées par l’OMS pour la Surveillance. 2eth ed. Genève: OMS; 2000. Organisation mondiale de la Santé (OMS), Département des Maladies transmissibles- Surveillance et Action. Normes recommandées par l’OMS pour la Surveillance. 2eth ed. Genève: OMS; 2000.
18.
go back to reference Desenclos JC, Dabis F. Epidémiologie de terrain, Méthodes et applications. Paris: John Libbey Eurotext; 2012. Desenclos JC, Dabis F. Epidémiologie de terrain, Méthodes et applications. Paris: John Libbey Eurotext; 2012.
19.
go back to reference World Health Organisation (WHO). Antiretroviral therapy for HIV infection in infants and children: towards universal access. Recommendations for a public health approach. Revision 2010. Geneva: WHO; 2010. World Health Organisation (WHO). Antiretroviral therapy for HIV infection in infants and children: towards universal access. Recommendations for a public health approach. Revision 2010. Geneva: WHO; 2010.
20.
go back to reference Desmonde S, Coffie P, Aka E, Amani-Bosse C, Messou E, Dabis F, et al. Severe morbidity and mortality in untreated HIV-infected children in a paediatric care programme in Abidjan, Côte d’Ivoire, 2004–2009. BMC Infect Dis. 2011;11:182.CrossRefPubMedPubMedCentral Desmonde S, Coffie P, Aka E, Amani-Bosse C, Messou E, Dabis F, et al. Severe morbidity and mortality in untreated HIV-infected children in a paediatric care programme in Abidjan, Côte d’Ivoire, 2004–2009. BMC Infect Dis. 2011;11:182.CrossRefPubMedPubMedCentral
21.
go back to reference Gasasira AF, Kamya MR, Ochong EO, Vora N, Achan J, Charlebois E, et al. Effect of trimethoprim-sulphamethoxazole on the risk of malaria in HIV-infected Ugandan children living in an area of widespread antifolate resistance. Malar J. 2010;9:177.CrossRefPubMedPubMedCentral Gasasira AF, Kamya MR, Ochong EO, Vora N, Achan J, Charlebois E, et al. Effect of trimethoprim-sulphamethoxazole on the risk of malaria in HIV-infected Ugandan children living in an area of widespread antifolate resistance. Malar J. 2010;9:177.CrossRefPubMedPubMedCentral
22.
go back to reference Kamya MR, Gasasira AF, Achan J, Mebrahtu T, Ruel T, Kekitiinwa A, et al. Effects of trimethoprim-sulfamethoxazole and insecticide-treated bednets on malaria among HIV-infected Ugandan children. AIDS. 2007;21(15):2059–66.CrossRefPubMed Kamya MR, Gasasira AF, Achan J, Mebrahtu T, Ruel T, Kekitiinwa A, et al. Effects of trimethoprim-sulfamethoxazole and insecticide-treated bednets on malaria among HIV-infected Ugandan children. AIDS. 2007;21(15):2059–66.CrossRefPubMed
23.
go back to reference Campbell JD, Moore D, Degerman R, Kaharuza F, Were W, Muramuzi E, et al. HIV-infected ugandan adults taking antiretroviral therapy with CD4 counts >200 cells/μL who discontinue cotrimoxazole prophylaxis have increased risk of malaria and diarrhea. Clin Infect Dis. 2012;54(8):1204–11.CrossRefPubMed Campbell JD, Moore D, Degerman R, Kaharuza F, Were W, Muramuzi E, et al. HIV-infected ugandan adults taking antiretroviral therapy with CD4 counts >200 cells/μL who discontinue cotrimoxazole prophylaxis have increased risk of malaria and diarrhea. Clin Infect Dis. 2012;54(8):1204–11.CrossRefPubMed
24.
go back to reference Manyando C, Njunju EM, D’Alessandro U, Van Geertruyden J-P. Safety and efficacy of co-trimoxazole for treatment and prevention of Plasmodium falciparum malaria: a systematic review. PLoS One. 2013;8(2), e56916.CrossRefPubMedPubMedCentral Manyando C, Njunju EM, D’Alessandro U, Van Geertruyden J-P. Safety and efficacy of co-trimoxazole for treatment and prevention of Plasmodium falciparum malaria: a systematic review. PLoS One. 2013;8(2), e56916.CrossRefPubMedPubMedCentral
25.
go back to reference Murray CJL, Ortblad KF, Guinovart C, Lim SS, Wolock TM, Roberts DA, et al. Global, regional, and national incidence and mortality for HIV, tuberculosis, and malaria during 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2014;384(9947):1005–70.CrossRefPubMedPubMedCentral Murray CJL, Ortblad KF, Guinovart C, Lim SS, Wolock TM, Roberts DA, et al. Global, regional, and national incidence and mortality for HIV, tuberculosis, and malaria during 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2014;384(9947):1005–70.CrossRefPubMedPubMedCentral
26.
go back to reference Mbeye NM, Ter Kuile FO, Davies M-A, Phiri KS, Egger M, Wandeler G, et al. Cotrimoxazole prophylactic treatment prevents malaria in children in sub-Saharan Africa: systematic review and meta-analysis. Trop Med Int Health. 2014;19(9):1057–67.CrossRefPubMedPubMedCentral Mbeye NM, Ter Kuile FO, Davies M-A, Phiri KS, Egger M, Wandeler G, et al. Cotrimoxazole prophylactic treatment prevents malaria in children in sub-Saharan Africa: systematic review and meta-analysis. Trop Med Int Health. 2014;19(9):1057–67.CrossRefPubMedPubMedCentral
27.
go back to reference Mermin J, Ekwaru JP, Liechty CA, Were W, Downing R, Ransom R, et al. Effect of co-trimoxazole prophylaxis, antiretroviral therapy, and insecticide-treated bednets on the frequency of malaria in HIV-1-infected adults in Uganda: a prospective cohort study. Lancet. 2006;367(9518):1256–61.CrossRefPubMed Mermin J, Ekwaru JP, Liechty CA, Were W, Downing R, Ransom R, et al. Effect of co-trimoxazole prophylaxis, antiretroviral therapy, and insecticide-treated bednets on the frequency of malaria in HIV-1-infected adults in Uganda: a prospective cohort study. Lancet. 2006;367(9518):1256–61.CrossRefPubMed
28.
go back to reference Greenhalgh S, Ndeffo M, Galvani AP, Parikh S. The epidemiological impact of HIV antiretroviral therapy on malaria in children. AIDS. 2015;29(4):473–82.CrossRefPubMedPubMedCentral Greenhalgh S, Ndeffo M, Galvani AP, Parikh S. The epidemiological impact of HIV antiretroviral therapy on malaria in children. AIDS. 2015;29(4):473–82.CrossRefPubMedPubMedCentral
29.
go back to reference Parikh S, Gut J, Istvan E, Goldberg DE, Havlir DV, Rosenthal PJ. Antimalarial Activity of Human Immunodeficiency Virus Type 1 Protease Inhibitors. Antimicrob Agents Chemother. 2005;49(7):2983–5.CrossRefPubMedPubMedCentral Parikh S, Gut J, Istvan E, Goldberg DE, Havlir DV, Rosenthal PJ. Antimalarial Activity of Human Immunodeficiency Virus Type 1 Protease Inhibitors. Antimicrob Agents Chemother. 2005;49(7):2983–5.CrossRefPubMedPubMedCentral
30.
go back to reference Skinner-Adams TS, McCarthy JS, Gardiner DL, Hilton PM, Andrews KT. Antiretrovirals as antimalarial agents. J Infect Dis. 2004;190(11):1998–2000.CrossRefPubMed Skinner-Adams TS, McCarthy JS, Gardiner DL, Hilton PM, Andrews KT. Antiretrovirals as antimalarial agents. J Infect Dis. 2004;190(11):1998–2000.CrossRefPubMed
32.
go back to reference Achan J, Kakuru A, Ikilezi G, Ruel T, Clark TD, Nsanzabana C, et al. Antiretroviral Agents and Prevention of Malaria in HIV-Infected Ugandan Children. N Engl J Med. 2012;367(22):2110–8.CrossRefPubMedPubMedCentral Achan J, Kakuru A, Ikilezi G, Ruel T, Clark TD, Nsanzabana C, et al. Antiretroviral Agents and Prevention of Malaria in HIV-Infected Ugandan Children. N Engl J Med. 2012;367(22):2110–8.CrossRefPubMedPubMedCentral
33.
go back to reference Whitworth J, Morgan D, Quigley M, Smith A, Mayanja B, Eotu H, et al. Effect of HIV-1 and increasing immunosuppression on malaria parasitaemia and clinical episodes in adults in rural Uganda: a cohort study. Lancet. 2000;356(9235):1051–6.CrossRefPubMed Whitworth J, Morgan D, Quigley M, Smith A, Mayanja B, Eotu H, et al. Effect of HIV-1 and increasing immunosuppression on malaria parasitaemia and clinical episodes in adults in rural Uganda: a cohort study. Lancet. 2000;356(9235):1051–6.CrossRefPubMed
34.
go back to reference Olusegun Akinbo F, Omoregie R. Plasmodium falciparum infection in HIV-infected patients on highly active antiretroviral therapy (HAART) in Benin City. Nigeria J Res Health Sci Winter-Spring. 2012;12(1):15–8. Olusegun Akinbo F, Omoregie R. Plasmodium falciparum infection in HIV-infected patients on highly active antiretroviral therapy (HAART) in Benin City. Nigeria J Res Health Sci Winter-Spring. 2012;12(1):15–8.
35.
go back to reference Initiative développement (ID), Sidaction. Guide de prise en charge de l’infection par le VIH chez l’enfant. Manuel pour les personnels impliqués dans la prise en charge pédiatrique du VIH. Paris: Grandir; 2010. Initiative développement (ID), Sidaction. Guide de prise en charge de l’infection par le VIH chez l’enfant. Manuel pour les personnels impliqués dans la prise en charge pédiatrique du VIH. Paris: Grandir; 2010.
37.
Metadata
Title
Effect of cotrimoxazole prophylaxis on the incidence of malaria in HIV-infected children in 2012, in Abidjan, Côte d’Ivoire: a prospective cohort study
Authors
Aïda Mounkaila Harouna
Madeleine Amorissani-Folquet
François Tanoh Eboua
Sophie Desmonde
Sylvie N’Gbeche
Edmond Addi Aka
Kouakou Kouadio
Brou Kouacou
Karen Malateste
Clarisse Bosse-Amani
Patrick Ahuatchi Coffie
Valeriane Leroy
for the IeDEA paediatric West African Study Group
Publication date
01-12-2015
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2015
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-015-1009-6

Other articles of this Issue 1/2015

BMC Infectious Diseases 1/2015 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.